Current efforts to develop VAR2CSA‐based vaccines to prevent placental malaria is the most advanced example of a PfEMP1‐based approach to malaria vaccination, as several such vaccines are currently in clinical trials.343, 344, 345, 346, 347 However, it is conceivable that development of vaccines to prevent severe malaria in children, including CM, might be possible using a similar strategy.193 An obvious goal would be vaccines eliciting a broadly reactive antibody response preventing, and ideally reversing, adhesion of IEs to ICAM‐1 and EPCR, which appear as key receptors in CM pathogenesis. This evidence concerns the gene ICAM1 and malaria.